Tarsus Pharmaceuticals, Inc. TARS Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The official record: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tarsus Pharmaceuticals, Inc.'s financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tarsus Pharmaceuticals, Inc.'s financing cash flow?
- Tarsus Pharmaceuticals, Inc. (TARS) reported financing cash flow of $1.2M in Q1 2026.
- How has Tarsus Pharmaceuticals, Inc.'s financing cash flow changed year-over-year?
- Tarsus Pharmaceuticals, Inc.'s financing cash flow decreased by 99.1% year-over-year, from $136.56M to $1.2M.
- What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s financing cash flow?
- Over 3 years (2022 to 2025), Tarsus Pharmaceuticals, Inc.'s financing cash flow has grown at a 15.1% compound annual growth rate (CAGR), from $94.12M to $143.39M.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.